Synthesis and computational study of 4-hydroxylbenzamide analogous as potential anti-breast cancer agent
Due to their role in cell growth and survival, HDAC (II), JAK 2 and EGFR receptors are important targets in many chemotherapies that aim to produce their biological response in malignancy solid tumors. In this work, several 4-hydroxybenzamide analogues coupled with 1,3-benzodioxole, a,ß-unsaturated...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/182e3f267666411a9cef620cc101cd8f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Due to their role in cell growth and survival, HDAC (II), JAK 2 and EGFR receptors are important targets in many chemotherapies that aim to produce their biological response in malignancy solid tumors. In this work, several 4-hydroxybenzamide analogues coupled with 1,3-benzodioxole, a,ß-unsaturated carbonyl, and tert-butyl ester bases small molecules were synthesized via imidation, EDC coupling, and etherification reactions, then bio-active 4-hydroxybenzamide analogues were studied using quantum calculations and molecular docking. The Frontier molecular orbitals and energy gap values were calculated using Time-Dependent Density Functional Theory (TD-DFT). Docking results showed A and E as potent JAK2 inhibitors. B, C, and F may be good HDAC II inhibitors. D may act as a potent EGFR inhibitor. These were followed by cytotoxic evaluation of 4-hydroxybenzamide analogues on human estrogen receptor breast cancer cells (MCF-7), metastatic breast adenocarcinome cancer cells (MDA-MB-231), and fibroblast cells (NIH/3T3) respectively. Molecule E was found to have insignificant apoptosis against MCF 7 cell line and MDM-MD-231 cell lines with IC50 value 5.0 µg⁄mL and 5.0 µg⁄mL respectively. |
|---|